Alnylam announces planned ceo leadership transition

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today the planned ceo transition of john maraganore, ph.d., to yvonne greenstreet, mbchb, at year-end 2021. dr. maraganore joined alnylam in 2002 as the company's founding ceo and has led the company's advancement of rnai therapeutics as a whole new class of innovative medicines, including four approved medicines marketed in over 25 countries around the world. dr. gr
ALNY Ratings Summary
ALNY Quant Ranking